Skip Navigation LinksHome > May 2014 - Volume 21 - Issue 3 > Sickle cell disease in India
Current Opinion in Hematology:
doi: 10.1097/MOH.0000000000000029
ERYTHROID SYSTEM AND ITS DISEASES: Edited by Narla Mohandas

Sickle cell disease in India

Colah, Roshan; Mukherjee, Malay; Ghosh, Kanjaksha

Free Access
Article Outline
Collapse Box

Author Information

National Institute of Immunohaematology, Parel, Mumbai, India

Correspondence to Dr Roshan Colah, PhD, Scientist F, National Institute of Immunohaematology (ICMR), 13th Floor, NMS Building, KEM Hospital Campus, Parel, Mumbai 400012, India. Tel: +91 022 24138518/19; e-mail: colahrb@gmail.com

Collapse Box

Abstract

Purpose of review

Sickle cell disease (SCD) poses a considerable health burden in India. This review focuses on the recent initiatives to understand the variable phenotypes, the role of hydroxyurea in patients with the Asian haplotype and the feasibility of newborn screening, awareness and control programs.

Recent findings

A systematic long follow up of patients in central India has documented the clinical events and the causes of significant morbidity and mortality. Fixed low dose hydroxyurea was sufficient for a clinical and hematological response in severe patients who had high baseline fetal hemoglobin (HbF) levels. Follow-up of birth cohorts of SCD babies initiated recently has shown that in central India babies clinically present with early and severe anemia, requiring blood transfusions, and septicemia, which are the most common complications, whereas babies from tribal communities in south Gujarat have no severe complications. Greater awareness has led to increasing requests for prenatal diagnosis.

Summary

SCD in India is not uniformly mild despite high fetal hemoglobin levels. The benefits of comprehensive care and hydroxyurea therapy have been demonstrated. Newborn screening is acceptable and is beginning to throw light on the natural history of the disease. The central and state governments are now supporting the establishment of centers for the diagnosis of patients and comprehensive care.

Back to Top | Article Outline

INTRODUCTION

Sickle cell disease (SCD) is a monogenic disorder with considerable clinical diversity. The presence of sickle hemoglobin was first described in India in 1952 in the tribal populations of the Nilgiri hills in south India [1]. Over the last 60 years, several studies have shown that SCD is a major health burden in India.

Back to Top | Article Outline

EPIDEMIOLOGY

The sickle cell gene is predominantly seen among the tribal populations in India, many of whom live in remote hilly regions and are often marginalized from the mainstream society. It is also prevalent among the scheduled castes and other background classes who are economically disadvantaged. Carrier frequencies range from 1 to 35% in many communities among these weaker and often neglected sections of society in different states (Fig. 1). There is wide variability in the prevalence of sickle cell trait (AS) and sickle cell anemia (SS) in population groups within small geographic areas [2–9,10▪]. The sickle cell gene is now also seen in some other communities at low frequencies [11–13].

FIGURE 1
FIGURE 1
Image Tools

Way back in 1988, the estimated number of sickle heterozygotes (AS) and homozygotes (SS) were 2 434 170 and 121 375, respectively, in India [3]. Since then many surveys have been done, and with the population of India now reaching 1.21 billion these figures would be much higher. A recent calculation using currently available data indicates that 50% of the total AS and SS neonates are born in only three countries, Nigeria, India and DR Congo. For SS neonates, the estimate for India was 42 016, which corresponds to 88% of the homozygous cases in Asia [14▪]. This emphasizes the need for a national registry for an accurate estimation.

Box 1
Box 1
Image Tools
Back to Top | Article Outline

CLINICAL FEATURES, MORBIDITY AND MORTALITY

The clinical presentation of SCD in India is relatively milder than in African patients; however, it is extremely variable in different tribal and non-tribal populations. Vasoocclusive crisis has been most commonly observed and leg ulcers and priapism are rare [5]. In Orissa, high frequencies of alpha thalassemia and high fetal hemoglobin (HbF) levels were observed as well as a higher frequency of splenomegaly, painful events, febrile illness and anemia [15]. In Maharashtra and Gujarat, the rate of painful crisis, hospitalization and infections was significantly higher among non-tribal populations in central India compared with tribal groups in south Gujarat. Vaccination in childhood, adequate intake of fluids and avoiding extreme temperatures have reduced the episodes of crisis [16].

Several studies have now documented the clinical events, morbidity and mortality in SCD patients from different regions. Seventy-nine deaths were reported among 1800 SCD patients in Orissa over 16 years. The main causes were attacks of pain, hepatic failure, fever, severe anemia and acute splenic sequestration. The fetal hemoglobin levels in these cases varied from less than 5 to 25% [17].

Perinatal outcomes have been studied in SS and AS individuals compared with control groups in Maharashtra and Orissa. Significant complications during pregnancy included severe anemia, vasoocclusive crises and toxemia. Neonatal outcomes such as preterm births, low birth weight, intrauterine deaths and early neonatal deaths were significantly higher than in the control group. However, successful pregnancies were achieved in 84.4% of women by meticulous antenatal management [18–20]. Managing pregnancies in women with SCD is a challenge and there are no data from India on pregnancy outcomes in different rural areas where facilities would be limited.

A retrospective study evaluated the clinical records of 316 children with sickle cell anemia (SCA) registered at Nagpur, with an average follow up of 5.8 ± 5.7 years. These children had been given penicillin prophylaxis and the clinical events were analyzed until they were started on hydroxyurea or until their last follow up. The median age at presentation was 3.84 years. There were 1725 hospitalizations in 282 patients, most commonly for severe anemia requiring blood transfusions. There were 175 episodes of severe febrile illness requiring hospitalization including 62 episodes of blood culture-proven bacterial septicemia in 42 patients. Splenic sequestration, cerebrovascular accidents and dactylitis were also common. Ten deaths were recorded during this period and they were attributed to severe anemia and hypoxic encephalopathy, severe bacterial infections, sequestration crises, and tuberculosis with AIDS, while in two deaths at home the reason was unknown [21]. This cohort demonstrates that in some children in central India SCD can be almost as severe as in patients with African haplotypes seen in the co-operative study [22]. Another study from Nagpur had also reported 1.25 episodes of sickle cell crises and 1.38 episodes of infections per patient per year among 325 children [23].

Morbidity in 85 young children with SCD who were hospitalized has been described. In this cohort, acute febrile illness was the most common event (31%) and bacteremia was proved in 20 events despite penicillin prophylaxis, followed by severe anemia requiring transfusions, acute painful events and hand foot syndrome, while splenic sequestration crises, acute chest syndrome and stroke were less common [24▪▪]. The causative organisms for infections were Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa, thus highlighting the difference in the pattern of bacteremia in children with SCD in India compared with Africa and other countries where Streptococcus pneumoniae and Haemophilus influenzae are the common causes for bacteremia [22,25].

Back to Top | Article Outline

GENETIC MODULATORS

Strong linkage of the βs gene with an independent Asian haplotype associated with high HbF levels was first shown in Orissa [26,27]. Subsequent studies in both tribal and non-tribal SCD patients from different states confirmed that this haplotype was predominant throughout India. However, around 10% of βS chromosomes are linked to the Cameroon, Benin, Bantu or other atypical haplotypes [28–34].

Back to Top | Article Outline
Fetal hemoglobin

HbF is a major modulator of the hematological and clinical presentation of SCD, as it can inhibit the deoxygenation-induced polymerization of sickle hemoglobin [35]. However, it has now been shown that the phenotype of adult patients in Saudi Arabia with the Arab–Indian haplotype is not benign despite high HbF levels [36▪]. Indian patients with this haplotype also have higher HbF levels but a very variable clinical presentation [16,34,37].

Variations in the β globin gene cluster alone cannot explain the differences in HbF levels seen among SCD patients, and there are other transacting factors that influence HbF levels and the number of F cells. Polymorphisms in three major quantitative trait loci (QTLs) (chromosome 11-Xmn1Gγ, chromosome 6q23-HBSIL-MYB and chromosome 2p16-BCL11A) have explained some of the variations seen in HbF levels in SCD [38,39].

In SCD patients with the Arab–Indian haplotype from Saudi Arabia, single nucleotide polymorphisms (SNPs) in the BCL11A and HBS1L-MYB that were earlier associated with HbF in other populations explained only 8.8% of the variation in HbF [40]. Our preliminary findings on three SNPs in the BCL11A gene in SCD patients are showing some association of the A allele of rs 4671393, the C allele of rs 11886868 and the G allele of rs 7557939 with higher HbF levels [41]. It has recently been shown that it is not just the amount of HbF or total number of F cells that are important but rather the ratio of HbF/F cell and the proportion of F cells that have adequate HbF to inhibit polymerization of sickle hemoglobin (HbS) that may predict the severity of the disease [42].

Back to Top | Article Outline
α-Thalassemia

α-Thalassemia in Indians is most frequently due to heterozygosity or homozygosity for the –α3.7 and –α4.2 deletions. Studies from Orissa had shown that the co-inheritance of α-thalassemia in SCD patients led to higher hemoglobin levels, red blood cell counts and HbA2 levels and lower reticulocyte counts, mean corpuscular volume (MCV), mean corpuscular hemoglobin and HbF levels, whereas the frequency of splenomegaly was not influenced by the α-genotype [43]. In western India, co-inherited α-thalassemia resulted in a milder presentation among tribal patients in Gujarat with fewer episodes of painful crises, acute chest syndrome, infections and the need for hospitalization and blood transfusions. However, splenomegaly was more common in them [44]. Similar findings were reported in another study from New Delhi [45].

Back to Top | Article Outline

OTHER GENETIC MODIFIERS

It is now well recognized that SNPs in many candidate genes, which are mediators of inflammation, vasoregulation, nitric oxide biology and hyperbilirubinemia, may potentially contribute to different subphenotypes in SCD patients [46]. However, it has been cautioned that although several candidate gene-association studies and genome-wide association studies have been undertaken for many subphenotypes, the functional SNP or the mechanism by which the disease is modified is unknown, as sample sizes were small and the findings were not validated [35].

Few such studies have been initiated in Indian patients. Nitric oxide plays a critical role in endothelial dysfunction. Three endothelial nitric oxide synthase (eNOS) gene polymorphisms showed significantly higher frequencies of mutant alleles in SCD patients [47]. They also influenced the age of menarche in females with SCD [48].

A hypercoagulable state in SCD has been well established. The prevalence of factor V Leiden (G1691A), methylene tetrahydrofolate reductase (MTHFR; C677T) and the prothrombin (G20210A) gene polymorphisms showed no significant differences in patients and controls in two of three studies [49–51].

Neutrophil activation plays an important role in the initiation and propagation of vasoocclusive crisis. The genotype frequencies of the H/R genotype of FcγRIIA and the NA1/NA1 genotype of FcγRIIIB were significantly decreased in SCD cases as compared to controls, with a decrease in the expression of CD62L [52].

Osteonecrosis is a serious complication in SCD. The frequency of one SNP (rs 7170178) (A/G, GG) in the ANXA2 gene was significantly higher in patients than in controls and was associated with sickle cell osteonecrosis [53]. However, no significant association was found between the −538 T/C polymorphism in bone morphogenic protein 4 (BMP 4) and orthopedic complications [54]. There was evidence to show that BMP–SMAD signaling components along with APT were overexpressed, mediated apoptosis and may be important in orthopedic complications in SCD [55].

Back to Top | Article Outline

INTERACTION OF SICKLE HEMOGLOBIN WITH OTHER HEMOGLOBINOPATHIES

Co-inheritance of the sickle gene with other hemoglobinopathies has led to disorders of variable severity.

Back to Top | Article Outline
Sickle hemoglobin–β-thalassemia

There are only a few reports on the clinical and hematological features of HbS–β-thalassemia from India. Seventeen patients from Orissa had the severe β+-thalassemia mutation IVS 1-5 (G → C) with very low levels of adult hemoglobin (3–5%). The clinical features were similar to SCA patients from this region [56]. Among 21 HbS–β-thalassemia patients from western India, the β0-thalassemia mutation CD 15 (G → A) was predominantly seen among tribals and the severe β+-thalassemia mutation IVS 1-5 (G → C) in non-tribals. HbS–β-thalassemia was clinically more severe among the non-tribals [57].

Back to Top | Article Outline
Sickle hemoglobin–δβ thalassemia

The Gγ(Aγδβ)0 thalassemia mutation is the commonest mutation causing δβ thalassemia in Indians [58]. Three cases of HbS–Gγ(Aγδβ)0 thalassemia were encountered in Orissa in two families. This condition was associated with frequent painful episodes, repeated hospitalization and transfusion requirements in two cases [59].

Back to Top | Article Outline
Sickle hemoglobin E disease

Sickle hemoglobin E (HbSE) disease is relatively uncommon with only around 30 cases reported so far, the largest series being from the Sultanate of Oman [60]. In India, eight cases of HbSE disease have been reported from Vellore in the south. They all presented in the second decade and had a mild clinical course presenting mainly with joint pains [61].

Back to Top | Article Outline
HbSDPunjab disease

There are only occasional reports on HbSDPunjab disease in the literature, although this condition is not uncommon in India where the prevalence of HbDPunjab is 1–3% in the north-western region [62]. Moderate anemia, mild jaundice and hepatosplenomegaly were reported in a 15-year-old Muslim girl [63]. We have seen 15 cases of HbSDPunjab disease over the last 10 years. The majority of them had a severe clinical presentation with painful episodes, severe anemia requiring frequent blood transfusions, febrile illness and avascular necrosis (our unpublished observation). A recent report from Orissa on 42 cases with HbSDPunjab disease showed that the frequency of vasoocclusive crises was similar to sickle homozygous cases. They found a negative correlation between HbF levels and the risk of vasoocclusive crises [64].

Back to Top | Article Outline
Sickle hemoglobin C disease

HbC is generally not seen in India and only one case of HbC–β0 thalassemia has been described [65]. Only one family with sickle HbC disease has been reported from Orissa, where two siblings with sickle HbC disease had a variable clinical presentation [66].

Back to Top | Article Outline

HYDROXYUREA THERAPY

Hydroxyurea is a powerful inducer of HbF production and is one of the main therapeutic agents used in the management of SCD. The majority of the studies that have proved the efficacy of hydroxyurea therapy in SCD have been in patients with the African haplotypes with lower baseline HbF levels [67–69], and there are limited data on the efficacy of hydroxyurea in Indian patients with SCD, many of whom have severe clinical manifestations despite higher baseline HbF levels.

The findings of four studies are summarized in Table 1[33,70–72]. In the first study, 77 severe SCD patients were enrolled for hydroxyurea therapy. A significant clinical response was seen in the majority of the patients. There was a significant but variable increase in HbF (Fig. 2) and F cells along with a significant increase in γ mRNA expression. The hemoglobin and MCV levels increased with some reduction in white blood cell and platelet counts, reticulocyte counts and serum bilirubin levels. The reduction in bilirubin levels was higher in patients with the (TA)7/7 repeats in the promoter region of the UGTIAI gene after hydroxyurea therapy. No significant toxicity was seen [33,73]. The maximum tolerated dose of hydroxyurea was not required for a therapeutic effect. Similar findings were shown in another smaller study from Chhattisgarh; however, the dose of hydroxyurea was higher [70].

Table 1
Table 1
Image Tools
FIGURE 2
FIGURE 2
Image Tools

Two further studies subsequently showed the efficacy of fixed low dose hydroxyurea in Indian patients. The first was a double-blind randomized controlled study in pediatric cases, mainly non-tribals from Nagpur [71]. A similar study from Orissa also showed an impressive improvement in the clinical and hematological parameters with minimal toxicity [72].

The recently concluded Pediatric Hydroxyurea Phase III Clinical Trial in infants (9–18 months) has proved the efficacy and safety of hydroxyurea [74].

The majority of the studies in the United States have used higher doses escalating to the maximum tolerated dose [75]. In India, a low dose would be more acceptable and economically viable as the majority of these patients are from a low-income group.

Back to Top | Article Outline

NEWBORN SCREENING

There is ample evidence from several countries that newborn screening and comprehensive care dramatically reduce morbidity and mortality of SCD patients in the first 5 years of life [76–79].

Newborn screening is in its infancy in India with pilot studies being undertaken in a few states over the last 3–4 years. Using a targeted screening approach, 88 babies with SCA, mainly non-tribals, were identified in central India [80]. They are being followed up regularly and provided comprehensive care. A high incidence of severe anemia and septicemia is being observed in this cohort (our unpublished observations). In Chhattisgarh, a 1-year pilot study identified five babies with SCD [81].

The feasibility of newborn screening among the tribal populations in rural areas in south Gujarat has also been demonstrated where 45 babies with SCA have been enrolled for comprehensive care. This cohort is showing a milder presentation (our unpublished observations).

Following up all the babies with SCD in these cohorts has been a challenge because of the low literacy in these families, long distances they have to travel to reach the center and seasonal migration for work, particularly among the tribal groups.

These studies will be the first to understand the natural history of SCD in India and need to be extended to other regions of this vast country.

Back to Top | Article Outline

PREVENTION AND CONTROL

In spite of improvements in management, there is considerable morbidity and mortality in Indian patients. With the successful implementation of awareness programs as well as screening and genetic counseling in antenatal clinics, there are a significant number of couples opting for prenatal diagnosis.

Our experience has shown that around 30% of couples come for prenatal diagnosis prospectively and the majority of them opt for termination of pregnancy when the fetus is affected [82,83]. Over 400 couples have undergone prenatal diagnosis of SCD at our Institute. The Indian Council of Medical Research (ICMR) is trying to establish regional centers for awareness, screening and control of sickle cell disorders in different states. Yet, there is a dilemma whether prenatal diagnosis for sickle cell disorders is justified for every pregnancy at risk, as some of these babies would have a mild disorder [84].

Back to Top | Article Outline

CONCLUSION

Although considerable work has been done on SCD in India, the majority of this has been done by individual centers and has had limited impact at the national level. Many patients in remote rural areas are not adequately managed and are often unable to reach a hospital. The need for networking and collaborative efforts has now been realized.

Under the National Rural Health Mission (NRHM), different state governments are establishing centers in different districts for the diagnosis and management of SCD patients. Gujarat, Chhattisgarh and Maharashtra have taken the lead in this. The ICMR has also initiated programs on SCD under their Tribal Health Research Forum. These government initiatives will strengthen the services for SCD patients in India. The need for North–South partnerships has been emphasized, as global collaborations will improve our understanding and management of the disease [85].

Back to Top | Article Outline

Acknowledgements

The authors would like to thank Mrs Preeti Pradeep for her help in preparing the article.

Back to Top | Article Outline
Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

  • ▪ of special interest
  • ▪▪ of outstanding interest

Back to Top | Article Outline

REFERENCES

1. Lehman H, Cutbush M. Sickle cell trait in southern India. Br Med J. 1952; 1:404–405.

2. Bhatia HM, Rao VR. Genetic atlas of Indian tribes. Bombay:Institute of Immunohaemtology (ICMR); 1986 .

3. Rao VR. Genetics and epidemiology of sickle cell anemia in India. ICMR Bull. 1988; 9:87–90.

4. Kaur M, Das GP, Verma IC. Sickle cell trait and disease among tribal communities in Orissa, Madhya Pradesh and Kerala. Indian J Med Res. 1997; 55:104–109.

5. Mohanty D, Mukherjee MB. Sickle cell disease in India. Curr Opin Hematol. 2002; 9:117–122.

6. Patra PK, Chauhan VS, Khodiar PK, et al. Screening for the sickle cell gene in Chhattisgarh state, India: an approach to a major public health problem. J Community Genet. 2011; 2:147–151.

7. Patel AP, Naik MR, Shah NM, et al. Prevalence of common hemoglobinopathies in Gujarat: an analysis of a large population screening programme. Natl J Community Med. 2012; 3:112–116.

8. Patel J, Patel B, Gamit N, Serjeant GR. Screening for the sickle cell gene in Gujarat India: a village based model. J Community Genet. 2013; 4:43–47.

9. Kaur M, Dani CBS, Singh M, et al. Burden of sickle cell disease among tribes of India: a burning problem. Int Res J Pharm Appl Sci. 2013; 3:60–80.

10▪. Mohanty D, Mukherjee MB, Colah RB, et al. Spectrum of hemoglobinopathies among the primitive tribes: a multicentric study in India. Asia Pac J Public Health. 2013; [Epub ahead of print]

This multicenter study describes the variable prevalence of the βS gene in 14 primitive tribes from four states.


11. Urade BP. Incidence of sickle cell anemia and thalassemia in central India. Open J Blood Disord. 2012; 2:71–80.

12. Bhukhanvala DS, Sorathiya SM, Shah AP, et al. Prevalence and hematological profile of β-thalassemia and sickle cell anemia in four communities in Surat City. Indian J Hum Genet. 2012; 18:167–171.

13. Dolai TK, Dutta S, Bhattacharyya M, Ghosh MK. Prevalence of hemoglobinopathies in Rural Bengal, India. Hemoglobin. 2012; 36:57–63.

14▪. Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013; 381:142–151.

Summary of global epidemiology showing that India is one of the three countries where 50% of all AS and SS neonates are born.


15. Kar BC, Devi S. Clinical profile of sickle cell disease in Orissa. Indian J Pediatr. 1997; 64:73–77.

16. Mukherjee MB, Lu CY, Ducrocq R, et al. Effect of alpha-thalassemia on sickle-cell anemia linked to the Arab-Indian haplotype in India. Am J Hematol. 1997; 55:104–109.

17. Kar BC. Deaths in sickle cell disease in India. Indian J Haematol Blood Transfus. 2005; 23:19–20.

18. Sonawane AS, Zodpey SP, Pralhadrao S. Pregnancy outcome in women with sickle cell disease/trait. J Obstet Gynecol India. 2005; 55:415–418.

19. Kale A, Panigrahi R, Sethi P. Perinatal outcome in pregnancy with sickle cell anemia. J Obstet Gynaecol India. 2008; 58:500–503.

20. Daigavane MM, Jena RK, Kar TJ. Perinatal outcome in sickle cell anemia: a prospective study. Hemoglobin. 2013; 37:507–515.

21. Jain D, Italia K, Sarathi V, et al. Sickle cell anemia from central India: a retrospective analysis. Indian Pediatr. 2012; 49:911–913.

22. Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative study of sickle cell disease. Blood. 1995; 86:776–783.

23. Patel AB, Athavale AM. Sickle cell disease in central India. Indian J Pediatr. 2004; 71:789–793.

24▪▪. Jain DL, Bagul AS, Shah M, Sarathi V. Morbidity pattern in hospitalized under five children with sickle cell disease. Indian J Med Res. 2013; 138:317–321.

A study describing the morbidity in young children highlighting the difference in the pattern of bacteremia in Indian patients as compared with patients in other countries.


25. Williams TN, Uyoga S, Macharia A, et al. Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study. Lancet. 2009; 374:1364–1370.

26. Kulozik AE, Wainscoat JS, Serjeant GR, et al. Geographical survey of beta S-globin gene haplotypes: evidence for an independent Asian origin of the sickle-cell mutation. Am J Hum Genet. 1986; 39:239–244.

27. Kulozik AE, Kar BC, Satapathy RK, et al. Fetal hemoglobin levels and beta (S) globin haplotypes in an Indian population with sickle cell disease. Blood. 1987; 69:1742–1746.

28. Labie D, Srinivas R, Dunda O, et al. Haplotypes in tribal Indians bearing the sickle gene: evidence for the unicentric origin of the beta S mutation and the unicentric origin of the tribal populations of India. Hum Biol. 1989; 61:479–491.

29. Oner C, Dimovski AJ, Olivieri NF, et al. Beta S haplotypes in various world populations. Hum Genet. 1992; 89:99–104.

30. Niranjan Y, Chandak GR, Veerraju P, Singh L. Some atypical and rare sickle cell gene haplotypes in populations of Andhra Pradesh, India. Hum Biol. 1999; 71:333–340.

31. Ramana GV, Chandak GR, Singh L. Sickle cell gene haplotypes in Relli and Thurpu Kapu populations of Andhra Pradesh. Hum Biol. 2000; 72:535–540.

32. Mukherjee MB, Surve RR, Gangakhedkar RR, et al. Beta-globin gene cluster haplotypes linked to the betaS gene in western India. Hemoglobin. 2004; 28:157–161.

33. Italia K, Jain D, Gattani S, et al. Hydroxyurea in sickle cell disease: a study of clinico-pharamacological efficacy in the Indian haplotype. Blood Cells Mol Dis. 2009; 42:25–31.

34. Bhagat S, Patra PK, Thakur AS. Fetal haemoglobin and β-globin gene cluster haplotypes among sickle cell patients in Chhattisgarh. J Clin Diagn Res. 2013; 7:269–272.

35. Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. Am J Hemtol. 2012; 87:795–803.

36▪. Alsultan A, Alabdulaali MK, Griffin PJ, et al. Sickle cell disease in Saudi Arabia: the phenotype of adults with the Arab-Indian haplotype is not benign. Br J Haematol. 2014; 164:597–604.

This article documents that SCD in adult patients in Saudi Arabia can be severe despite linkage to the Arab–Indian haplotype.


37. Mashon RS, Dash PM, Khalkho J, et al. Higher fetal hemoglobin concentration in patients with sickle cell disease in eastern India reduces frequency of painful crisis. Eur J Haematol. 2009; 83:383–384.

38. Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci U S A. 2008; 105:11869–11874.

39. Bae HT, Baldwin CT, Sebastiani P, et al. Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans. Blood. 2012; 120:1961–1962.

40. Ngo D, Bae H, Steinberg MH, et al. Fetal hemoglobin in sickle cell anemia: genetic studies of the Arab-Indian haplotype. Blood Cells Mol Dis. 2013; 51:22–26.

41. Upadhye D, Jain D, Nadkarni A, et al. Influence of single nucleotide polymorphisms in the BCL11A gene on Hb F levels and the clinical presentation of sickle cell disease in central India [abstract]. Indian J Haematol Blood Transf. 2013; 29:368

Abstr. 267


42. Steinberg MH, Chui DH, Dover GJ, et al. Fetal hemoglobin in sickle cell anemia: a glass half full? Blood. 2014; 123:481–485.

43. Kulozik AE, Kar BC, Serjeant GR, et al. The molecular basis of alpha thalassemia in India. Its interaction with the sickle cell gene. Blood. 1988; 71:467–472.

44. Mukherjee MB, Surve R, Tamankar A, et al. The influence of α-thalassemia on the hematological and clinical expression of sickle cell disease in western India. Indian J Med Res. 1998; 107:178–181.

45. Pandey S, Pandey S, Mishra RM, et al. Genotypic influence of α-deletions on the phenotype of Indian sickle cell anemia patients. Korean J Hematol. 2011; 46:192–195.

46. Steinberg MH. Genetic etiologies for phenotypic diversity in sickle cell anemia. Sci World J. 2009; 9:46–47.

47. Nishank SS, Singh MP, Yadav R, et al. Endothelial nitric oxide synthase gene polymorphism is associated with sickle cell disease patients in India. J Hum Genet. 2013; 58:775–779.

48. Nishank SS. Endothelial nitric oxide synthase (eNOS) gene polymorphism is associated with age of onset of menarche in sickle cell disease females in India. Mediterr J Hematol Infect Dis. 2013; 5:e2013036

49. Pandey SK, Meena A, Kishor K, et al. Prevalence of factor V Leiden G1691A, MTHFR C677T, and prothrombin G20210A among Asian Indian sickle cell patients. Clin Appl Thromb Hemost. 2012; 18:320–323.

50. Kangne HK, Jijina FF, Italia YM, et al. The prevalence of factor V Leiden (G1691A) and methylenetetrahydrofolate reductase C677T mutations in sickle cell disease in Western India. Clin Appl Thromb Hemost. 2013;

[Epub ahead of print]


51. Nishank SS, Singh MP, Yadav R. Clinical impact of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations among sickle cell disease patients of Central India. Eur J Haematol. 2013; 91:462–466.

52. Kangne HK, Jijina FF, Italia YM, et al. The Fc receptor polymorphisms and expression of neutrophil activation markers in patients with sickle cell disease from Western India. Biomed Res Int. 2013; 2013:e457656

53. Pandey S, Ranjan R, Pandey S, et al. Effect of ANXA2 gene single nucleotide polymorphism (SNP) on the development of osteonecrosis in Indian sickle cell patients: a PCR-RFLP approach. Indian J Exp Biol. 2012; 50:455–458.

54. Abhishek K, Sohail M, Kumar R, et al. Mutation -538 T/C in bone morphogenetic protein 4 does not increase the risk in sickle-cell disease with orthopedic complications but is strongly associated with increased LDH and uric acid level in Indian patients from Chhattisgarh and Jharkhand states. Clin Chim Acta. 2010; 411:664–670.

55. Abhishek K, Kumar R, Arif E, et al. Induced expression of bone morphogenetic protein-6 and Smads signaling in human monocytes derived dendritic cells during cell pathology with orthopedic complications. Biochem Biophys Res Commun. 2010; 396:950–955.

56. Kulozik AE, Bail S, Kar BC, et al. Sickle cell-beta+ thalassaemia in Orissa State, India. Br J Haematol. 1991; 77:215–220.

57. Mukherjee MB, Nadkarni AH, Gorakshakar AC, et al. Clinical, hematologic and molecular variability of sickle cell-β thalassemia in western India. Indian J Hum Genet. 2010; 16:154–158.

58. Nadkarni A, Wadia M, Gorakshakar A, et al. Molecular characterization of delta beta-thalassemia and hereditary persistence of fetal hemoglobin in the Indian population. Hemoglobin. 2008; 32:425–433.

59. Patel DK, Patel M, Mashon RS, et al. Clinical and molecular characterization of β(S) and Gγ (Aγδβ)0-thalassemia in eastern India. Hemoglobin. 2010; 34:604–609.

60. Knox-Macaulay HH, Ahmed MM, Gravell D, et al. Sickle cell-haemoglobin E (HbSE) compound heterozygosity: a clinical and haematological study. Int J Lab Hematol. 2007; 29:292–301.

61. Edison ES, Shaji RV, Chandy M, Srivastava A. Interaction of hemoglobin E with other abnormal hemoglobins. Acta Haematol. 2011; 126:246–248.

62. Srinivas U, Pati HP, Saxena R. Hemoglobin D-Punjab syndromes in India: a single center experience on cation-exchange high performance liquid chromatography. Hematology. 2010; 15:178–181.

63. Ghosh UC, Sen K, Narayan A, et al. Haemoglobin SD disease: rare case of jaundice. J Indian Med Assoc. 2012; 110:501–502.

64. Patel DK, Purohit P, Dehury S, et al. Fetal hemoglobin and alpha thalassemia modulate the phenotypic expression of HbSD-Punjab. Int J Lab Hematol. 2013;

[Epub ahead of print]


65. Kumar SM, Rana A, Handoo, et al. Case report of HbC/β0 thalassemia from India. Int J Lab Haem. 2007; 291:381–385.

66. Patel DK, Patel S, Mashon RS, et al. Diverse phenotypic expression of sickle cell hemoglobin C disease in an Indian family. Ann Hematol. 2011; 90:357–358.

67. Kinney TR, Helms RW, O’Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999; 94:1550–1554.

68. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005; 106:2269–2275.

69. Steinberg MH, McCarthy WF, Castro O, et al. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients’ Follow-Up The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010; 85:403–408.

70. Singh H, Dulhani N, Kumar BN, et al. Effective control of sickle cell disease with hydroxyurea therapy. Indian J Pharmacol. 2010; 42:32–35.

71. Jain DL, Sarathi V, Desai S, et al. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin. 2012; 36:323–332.

72. Patel DK, Mashon RS, Patel S, et al. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India. Hemoglobin. 2012; 36:409–420.

73. Italia KY, Jijina FF, Jain D, et al. The effect of UGT1A1 promoter polymorphism on bilirubin response to hydroxyurea therapy in hemoglobinopathies. Clin Biochem. 2010; 43:1329–1332.

74. Thornburg CD, Files BA, Luo Z, et al. BABY HUG Investigators Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood. 2012; 120:4304–4310.

75. Ware RE. How I use hydroxyurea? Blood. 2010; 115:5300–5311.

76. Serjeant GR, Serjeant BE. Management of sickle cell diseae: lessons from the Jamaican cohort study. Blood Rev. 1993; 793:137–145.

77. Michlitsch J, Azimi M, Hoppe C, et al. Newborn screening for hemoglobinopathies in California. Pediatr Blood Cancer. 2009; 52:486–490.

78. Bain BJ. Neonatal/newborn hemoglobinopathy screening in Europe and Africa. J Clin Pathol. 2009; 62:53–56.

79. Benson JM, Therrell BL Jr. History and current status of newborn screening for hemoglobinopathies. Semin Perinatol. 2010; 32:134–144.

80. Jain DL, Sarathi V, Upadhye D, et al. Newborn screening shows a high incidence of sickle cell anemia in central India. Hemoglobin. 2012; 36:316–322.

81. Panigrahi S, Patra PK, Khodiar PK. Neonatal screening of sickle cell anemia: a preliminary report. Indian J Pediatr. 2012; 79:747–750.

82. Colah R, Surve R, Nadkarni A, et al. Prenatal diagnosis of sickle syndromes in India: dilemmas in counselling. Prenat Diagn. 2005; 25:345–349.

83. Colah RB, Gorakshakar AC, Nadkarni AH. Invasive & noninvasive approaches for prenatal diagnosis of haemoglobinopathies: experiences from India. Indian J Med Res. 2011; 134:552–560.

84. Kumar R, Panigrahi I, Dalal A, Agarwal S. Sickle cell anemia: molecular diagnosis and prenatal counselling – SGPGI experience. Indian J Pediatr. 2012; 79:68–74.

85. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010; 115:4331–4336.

Keywords

epidemiology; hydroxyurea therapy; India; morbidity; sickle cell disease

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.